Added to YB: 2026-05-12
Pitch date: 2026-05-10
CPH.TO [neutral]
Cipher Pharmaceuticals Inc.
-6.46%
current return
Author Info
Petty Cash shares microcap investing ideas (mainly in Canada) in their newsletter. Sign up for the newsletter.
Company Info
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with acute coronary syndrome; and Natroba for the topical treatment of head lice and scabies infestations in adult and pediatric patients.
Market Cap
CAD 366.1M
Pitch Price
CAD 19.51
Price Target
N/A
Dividend
N/A
EV/EBITDA
13.18
P/E
12.09
EV/Sales
7.07
Sector
Pharmaceuticals
Category
growth
Cipher Pharmaceuticals Q1 2026 Update – CPH.to
CPH.TO (earnings): Q1 rev $12.5M (+4% YoY), adj EBITDA $7.7M (+25% YoY), 62% EBITDA margin (+10%). Natroba rev $6.9M (+3%), gross margin 87% vs 77%. DTC launch underway, driving higher net pricing via commercial payer mix. Debt-free, NCIB renewed, evaluating upsized credit facility for M&A. MOB-015 U.S. Ph3 potential catalyst. 12.1x EV/EBITDA, 13.1x EV/FCF.
Read full article (2 min)